RT Journal Article
SR Electronic
T1 Hybrid immunity improves the immune response after fourth Covid-19 vaccine dose in individuals with medical conditions predisposing to severe Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.21.23300374
DO 10.1101/2023.12.21.23300374
A1 Ekström, Nina
A1 Leino, Tuija M.
A1 Juutinen, Aapo
A1 Lehtonen, Toni
A1 Haveri, Anu
A1 Liedes, Oona
A1 Vara, Saimi
A1 Salo, Heini
A1 Palmu, Arto A.
A1 Nohynek, Hanna
A1 Martelius, Timi
A1 Melin, Merit
YR 2023
UL http://medrxiv.org/content/early/2023/12/24/2023.12.21.23300374.abstract
AB Background Data on Covid-19 booster vaccinations and subsequent infections on immune responses in the immunocompromised is limited. We studied antibody responses after the fourth dose and subsequent breakthrough infection to define patient groups benefiting most from boosters.Methods In Finland, fourth vaccine (booster) doses were first recommended for severely immunocompromised individuals, whom we invited to participate in 2022. We assessed spike protein specific IgG antibody levels and neutralizing antibodies (NAb) against the ancestral and Omicron BA.1 strains one month after the fourth dose from 488 adult participants and compared to the levels of 35 healthy controls after 3 doses. We used Bayesian generalized linear modelling to assess factors explaining antibody concentrations after the fourth dose. We assessed vaccine-induced and hybrid immunity six months after the last vaccine dose.Results Chronic kidney disease (CKD) and immunosuppressive therapy (IT) were identified as factors explaining sub-optimal antibody responses. The proportion of participants with a normal antibody response and NAbs were significantly lower in CKD patients as compared to controls. By the 6-month sampling one third of the participants became infected, which enhanced antibody levels notably in most immunocompromised participants.Conclusions Impaired antibody responses, especially NAbs against the Omicron lineage, predict limited protection in individuals with CKD, and highlight the need for alternative pharmaceutical preventive strategies. Vaccination strategies should take into account development of robust hybrid immunity responses also among the immunocompromised.Competing Interest StatementThe Finnish Institute for Health and Welfare (THL) has until September 2022 conducted Public-Private Partnerships with vaccine manufacturers and has previously received research funding for studies unrelated to COVID-19 from GlaxoSmithKline Vaccines (N.E., A.A.P., and M.M. as investigators), Pfizer (A.A.P.), and Sanofi Pasteur (A.A.P.). M.M., T.M. and H.N. are members of the Finnish National Advisory Committee on Vaccines. H.N. is chair of the WHO Strategic Advisory Group of Experts. A.A.P. is currently an employee of FVR, Finnish vaccine research, which collaborates with all major vaccine manufacturers, including Pfizer and Moderna, in clinical and RWE research. HS is and adviser to Adult Immunization Board (AIB) based at the University of Antwerp and Florence (travel expenses reimbursed), meetings funded by an unrestricted grant from Vaccines Europe.Funding StatementThis study was funded by the Finnish Institute for Health and Welfare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the National Committee on Medical Research Ethics (TUKIJA/347/2021) and the Finnish Medicines Agency Fimea as the regulatory authority (EudraCT 2021-004788-29). Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data presented in this study is available on a reasonable request from the corresponding author.